XML 38 R27.htm IDEA: XBRL DOCUMENT v3.19.1
Long-Term Investments (Tables)
 3 Months Ended
Mar. 31, 2019
Schedule of ownership percentages of investee

   Ownership percentage    
   March 31,   December 31,   Accounting
Name of related party  2019   2018   treatment
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.72%   0.72%  Cost Method
BioHopeKing Corporation   7.13%   7.13%  Cost Method
BioFirst Corporation   16.14%   15.84%  Equity Method
Rgene   31.63%   31.62%  Equity Method
Schedule of extent the investee relies

Name of related party   The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation   Loaned from the investee and provides research and development support service
Rgene   Collaborating with the Company to develop and commercialize drugs
Schedule of long-term investment

   March 31,
2019		   December 31,
2018		 
   (Unaudited)     
Non-marketable Cost Method Investments, net        
Braingenesis Biotechnology Co., Ltd.  $7,147   $7,213 
Genepharm Biotech Corporation   21,819    22,021 
BioHopeKing Corporation   1,938,480    1,956,429 
Sub total   1,967,446    1,985,663 
Equity Method Investments, net          
BioFirst Corporation   1,440,317    1,502,506 
Rgene Corporation   -    - 
Total  $3,407,763   $3,488,169 
Schedule of equity investments

   Three Months Ended
Mar 31,		 
   2019   2018 
   (Unaudited) 
Share of equity method investee losses  $(66,205)  $(38,567)
Impairments   -    - 
Total losses on equity investments  $(66,205)  $(38,567)
BioFirst [Member]  
Schedule of balance sheets

   March 31,
2019		   December 31,
2018		 
   (Unaudited)     
Current Assets  $7,324,390   $7,551,898 
Noncurrent Assets   1,639,340    1,608,460 
Current Liabilities   1,805,325    1,648,206 
Noncurrent Liabilities   36,502    - 
Shareholders' Equity   7,121,903    7,512,152 
Schedule of statements of operation

   Three Months Ended
March 31,		 
   2019   2018 
   (Unaudited) 
Net sales  $10,334   $10,022 
Gross profit   1,882    2,372 
Net loss   (307,034)   (178,294)
Share of losses from investments accounted for using the equity method   (66,205)   (38,567)
Rgene [Member]  
Schedule of balance sheets
   March 31,
2019		   December 31,
2018		 
   (Unaudited)     
Current Assets  $94,305   $98,168 
Noncurrent Assets   39,541    14,779 
Current Liabilities   292,588    261,685 
Noncurrent Liabilities   11,424    - 
Shareholders' Equity (Deficit)   (170,166)   (148,738)
Schedule of statements of operation

   Three Months Ended
March 31,		 
   2019   2018 
   (Unaudited) 
Net sales  $-   $- 
Gross Profit   -    - 
Net loss   (22,662)   (36,041)
Share of loss from investments accounted for using the equity method   -    -